Therefore, this study evaluated the benefit of a combined approach to identify individuals at risk of severe illness due to COVID-19 using urinary L-type fatty acid-binding protein (L-FABP) levels and the Sequential Organ Failure Assessment (SOFA) scores calculated from blood tests for pre-admission screening of patients with COVID-19. The gene discussed is FABP1; the disease is COVID-19.